Torre D, Speranza F, Martegani R, Zeroli C, Banfi M, Airoldi M
Division of Infectious Diseases, Regional Hospital, Varese, Italy.
J Infect. 1998 Jul;37(1):15-8. doi: 10.1016/s0163-4453(98)90217-1.
a retrospective study was designed to evaluate efficacy and tolerance of trimethoprim-sulphamethoxazole (TMP-SMZ) in AIDS patients with cerebral toxoplasmosis (TE).
we reviewed 471 patients with AIDS, and we analysed 71 AIDS patients with TE, who received intravenous therapy with TMP-SMZ (TMP: 10 mg/kg/day, SMZ: 50 mg/kg/day) for 4 weeks.
35 patients (49.2%) had a complete regression of clinical signs, and a complete resolution of radiological lesions was noted in 41 patients (57.7%). Improvement of clinical signs and radiological lesions were observed in 27 patients (38%), and in nine patients (12.6%), respectively. In contrast, nine patients (12.6%) did not show any clinical change, or worsened. Twenty-two patients (30.9%) suffered from adverse cutaneous reactions, whereas many patients had haematological toxicity.
TMP-SMZ seems to be an efficient therapy for TE in AIDS patients, although further prospective, randomized therapeutic trials are required to confirm these results.
设计一项回顾性研究以评估复方新诺明（TMP-SMZ）治疗艾滋病合并脑弓形虫病（TE）患者的疗效和耐受性。
我们回顾了471例艾滋病患者，并分析了71例接受TMP-SMZ静脉治疗（TMP：10mg/kg/天，SMZ：50mg/kg/天）4周的艾滋病合并TE患者。
35例患者（49.2%）临床体征完全消退，41例患者（57.7%）影像学病变完全消失。27例患者（38%）临床体征和影像学病变有所改善，分别有9例患者（12.6%）出现上述情况。相比之下，9例患者（12.6%）无任何临床变化或病情恶化。22例患者（30.9%）出现皮肤不良反应，而许多患者有血液学毒性。
TMP-SMZ似乎是治疗艾滋病合并TE患者的有效疗法，尽管需要进一步进行前瞻性随机治疗试验来证实这些结果。
